Pharmaceutical stocks are the shares of healthcare firms that create, manufacture, and distribute pharmaceutical products, such as pharmaceuticals, medicines, and vaccines. In times of political or economic turmoil, it is prevalent to invest in pharmaceutical stocks. For instance, due to the Covid-19 crisis, pharmaceutical businesses are in high demand for their products and equipment, which has increased their share price and worth.
This article provides a list of worldwide pharmaceutical shares with some of the most significant market capitalizations, dividend yield percentages, and total stock value, as measured by stock market indices such as the S&P 500 and FTSE 100. These details are correct as of February 2021. Our trading platform includes spread betting and CFD trading on blue-chip stocks, large-cap stocks, and pharma penny stocks; thus, continue reading to discover how you may trade penny pharmaceutical stocks with us.
A Brief Introduction to Penny Pharmaceutical Stocks
In recent years, biotech and pharmaceutical penny stocks have gained particular interest to investors, as companies such as Novavax and Pharma Mar have frequently evolved into huge worldwide organizations. During the Covid-19 epidemic, penny stocks in the pharmaceutical industry grew in popularity as several small companies rushed to create a coronavirus vaccine, rivaling their larger counterparts.
For instance, Pharma Mar said that its coronavirus therapy was almost 2,800 times more successful than its biotech competitor, Gilead Sciences. Before the overview of the pandemic in early 2020, Pharma Mar's stock price traded for less than $5 a share, and since then, it has risen steadily. The same is true for Inovio Pharmaceuticals, which was considered a pharmaceutical penny stock until February 2020, when its share price increased about tenfold.
The pharmaceutical business is a subsector of the broader healthcare industry, and these companies remain working 365 days a year, regardless of the global climate. Share prices often reflect investors' perceptions of a company's value and any profit or loss that may follow from starting a trade. In order to determine the value of pharma stocks, it is necessary to analyze company fundamentals: the internal and external elements that may impact the business's performance. This is a component of fundamental analysis, which most traders will conduct before initiating a long-term position but less frequently before opening a short-term one. Price-to-earnings (P/E) ratios assist in valuing a company's stock relative to its competitors.
Investors in pharmaceutical stocks choose equities with a high dividend yield, which indicates that the firm is likely to pay continuous dividends. Paying dividends to investors may improve their loyalty and faith in future performance and dividend payments.
The total return is also an excellent measure of the performance of healthcare stocks. It measures the rate of return on an investment over some time using interest, capital gains, and dividends. These factors may be utilized to determine the worth of leading pharmaceutical stocks.
1. GlaxoSmithKline (GSK)
GSK is a worldwide pharmaceutical corporation headquartered in London that manufactures and markets vaccines, medications, and other healthcare-related goods. Its diverse activities make it a dependable pharmaceutical company and contribute to a trader's risk portfolio diversification. Because relatively low-risk stocks tend to appeal to long-term investors, it is now one of the most popular U.K. pharmaceutical stocks.
2. Adhera Therapeutics (ATRX)
According to the business's news release, Adhera Therapeutics is "a clinical-stage biopharmaceutical company focused on finding advanced therapeutic candidates that may qualify for expedited development routes." The Company has recently licensed two medication candidates from the Melior Discovery family of companies.
Adhera has two primary focuses. First, the Company is "developing MLR-1023 (tolimidone) as a novel medicine for Type I diabetes, emphasizing C-peptide positive patients. MLR-1023, a lyn kinase activator, has exhibited excellent clinical safety and tolerability in Phase 2a and Phase 2b Type 2 diabetes investigations including more than 700 patients."
Second, the Company's MLR-1019 (armesocarb) is the only medicine that treats both movement and non-movement symptoms of Parkinson's disease (P.D.).
Due to a substantial awareness effort, Parkinson's disease is a primary trigger for ATRX and other penny stocks related to the ailment. In addition, a study from the Centers for Disease Control and Prevention from 2020 "indicates a roughly 30 percent increase in type 1 diabetes (T1D) diagnoses in the United States, with the incidence among diverse young demographics rising most rapidly."
3. AbbVie (ABBV)
AbbVie is a spin-off of Abbott Laboratories committed to the global treatment of chronic autoimmune disorders, such as blood malignancies, Parkinson's, and Crohn's. In June of 2019, it bought the Irish biopharmaceutical company Allergan. Whose combined revenue has resulted in tremendous growth of the business. This has raised the share price of AbbVie. It also delivers steady dividends of a high proportion to investors.
4. Brickell Biotech Inc. (BBI)
Brickell Biotech is one of the most popular (and inexpensive) biotech penny stocks. We have been discussing this firm for the past few weeks, and the market appears to have lately taken notice. Following last month's earnings report and forecast, the public's attention has been drawn to the prescription medicines firm.
Following acquiring the rights to its BBI-02 candidate, Brickell disclosed that it intends to extend its immunology and inflammation therapeutic pipeline. According to the business, the beginning of Phase 1 research for BBI-02 to treat autoimmune and inflammatory illnesses remains on pace for this quarter.
"We continue to execute toward a mid-2022 NDA filing for sofpironium bromide gel, 15% for the treatment of primary axillary hyperhidrosis, and consider all available options to achieve commercial product success," Brickell CEO Robert Brown noted. In recent weeks, investors have honed in on BBI stock in light of this view and anticipated upcoming milestones.
5. Diffusion Pharmaceuticals (DFFN)
Diffusion Pharmaceuticals is a life sciences firm specializing in innovative medicines that improve the body's ability to transport oxygen. Trans sodium crocetin (TSC), the Company's flagship product, enables tissues with low oxygen levels to obtain the essential chemical element. This condition, known as hypoxia, is a significant complication in several therapeutic procedures.
The TSC product from Diffusion has enormous significance for combating the coronavirus epidemic. Hypoxia is a "often ignored clinical condition in Covid-19 patients," according to a paper from BMJ Journals. The difficulty for frontline medical personnel is that patients may exhibit little respiratory discomfort while having a low oxygen saturation, which can lead to severe infections.
Therefore, the BMJ "emphasizes the significance of a thorough clinical assessment, including tests of oxygen saturation, for suspected or confirmed patients." DFFN is a currently relevant bet among biotech penny stocks in this context.
However, how long will its importance endure? Due to the pandemic's unpredictability, we would not stake the farm on DFFN based just on its Covid-19 prescription. Instead, we would consider Diffusion's other TSC applications before making a choice.
6. Gilead Sciences (GILD)
Gilead is a biopharmaceutical business in the United States that specializes in developing antiviral treatments for diseases frequently neglected by other healthcare companies. This covers the treatment of HIV, liver illness, and other related inflammatory disorders. Gilead's stock price increased by 5% in a couple of days on the announcement that they were a leading competitor in the early 2020 Covid-19 vaccine race.
7. Halberd (HALB)
If you are familiar with Halberd, you are likely aware of its significance to the Covid-19 epidemic. According to the Company's website, their proprietary extracorporeal therapy " applies to several difficult-to-treat blood-borne and neurologic disorders, including Covid-19" and other viruses.
Frankly, we are uncertain how the Covid-19 aspect will affect Halberd and the other penny companies on this list. Indeed, science is quite exciting. However, now that Merck (NYSE: MRK) has entered the narrative with its antiviral Covid tablet, pandemic-related catalysts may wane. However, the Merck danger is not a certainty, so we shall see.
Besides the global health crisis, Halberd makes a highly persuasive approach to neurological disorders, notably post-traumatic stress disorder. We need a remedy for PTSD due to the numerous conflicts in which our service members found themselves following the September 11 attacks.
The U.S. Department of Veterans Affairs announces that 11 and 20 percent of veterans who participated in Operations Iraqi Freedom and Enduring Freedom have PTSD in any given year.
HALB is dangerous, especially in comparison to other penny stocks. Do not let your emotions or patriotism cloud your judgment in this situation.
8. Idera Pharmaceuticals (IDRA)
Idera Pharmaceuticals soared in Tuesday's opening hour of trade. Since January, the biotechnology penny stock has traded with some of the highest volumes. There were no accompanying headlines to the action. Nonetheless, information from the end of March might offer insight into the nature of speculative activity in IDRA stock.
Idera's fourth quarter and full-year financial figures reveal a more robust growth rate than in the previous year. Specifically, the Company's loss per share was much improved year-over-year, coming in at $0.08 compared to $2.11 in Q4 2020. However, performance was not always what drew the market's attention.
Idera's Chief Executive Officer, Vincent Milano, stated, "Additionally, we have asked JMP Securities, a Citizens Company, our current partner and advisor on business development activities, to expand their current scope of work beyond acquisition or in-licensing opportunities to include additional strategic alternatives for the Company."
9. Therapeutic Solutions International (TSOI)
Therapeutic Solutions International focuses on immunological regulation for treating specific disorders, according to a press release. In August of this year, Therapeutic Solutions' management reported that "a series of preclinical investigations required by the United States Food and Drug Administration (FDA) to launch Phase I/II clinical trials" had been completed.
In controversy is the Company's proprietary JadiCell therapy for chronic traumatic encephalopathy (CTE). Sports fans are aware that repeated concussive and sub-concussive blows cause CTE to the brain over several years, commonly discovered in football players. This disorder is marked by memory loss, impulsive/irrational conduct, poor judgment, violence, depression, and dementia."
Given the prominence of CTE, Therapeutic Solutions may experience a rise in public opinion. This is particularly true now that amateur, collegiate, and professional sports have resumed. TSOI's visibility may expand when it transitions from Covid bubbles and other security precautions to the chronic illnesses that affect high-contact sports.
10. AstraZeneca (AZN)
AstraZeneca performs its R&D in three worldwide regions: Cambridge, United Kingdom; Maryland, United States; and Molndal, Sweden. It is one of the most sophisticated cardiovascular, respiratory, and autoimmune prescription drug developers. AstraZeneca's share price has risen in recent months due to the pandemic, making it one of the fastest-growing top pharma companies in 2022. The Oxford-AstraZeneca vaccine was the second to be authorized by the MHRA and delivered to the general public in December 2020; this will continue in the following months.
How to Invest in Pharmaceuticals
Pharmaceutical shares are accessible for purchase and sale on the stock market, and some investors prefer to investigate pharma companies through ETF trading. Most of the time, these shares are listed on a primary stock market, such as the London or New York stock exchanges. This approach entails purchasing and long-term ownership of a share, which needs you to acquire the asset.
How to Trade Pharmaceutical Stocks with Top1 Markets
You may trade pharmaceutical stocks using spread betting and CFDs on our platform (contracts for difference). Spread betting offers tax-free trading on the price fluctuations of stocks; nevertheless, tax status is dependent on individual circumstances and can change or vary in jurisdictions other than the United Kingdom. Additionally, you may invest in pharmaceutical equities via significant stock indexes, such as the FSTE 100, which includes businesses such as GSK and AstraZeneca.
With these derivatives, you establish a position based on whether you believe the share price of a pharmaceutical company will grow or decrease, depending on the market's movement. This will result in a profit or loss. CFDs are contractual arrangements to trade the difference between an asset's opening and closing prices. Profits and losses are also dependent on stock market fluctuations.
Please be aware that spread betting and CFDs are leveraged products, meaning you simply need to deposit the total trade value to obtain market exposure. Profits and losses are so exaggerated.
Pharmaceutical Stock News
When trading pharma stocks, it is essential to be current on global news and significant events. The stock market may be volatile, and announcements frequently cause share values to move. Our skilled market analysts provide frequent material in our news and analysis area so that you have all the knowledge you need to trade on pharmaceutical stocks that are on the rise.
Final Thoughts
Investing in penny pharmaceutical stocks is now a high-risk, high-reward endeavor. However, this is true for all penny stocks, as most firms in this category are either still in their early phases of growth or have yet to achieve widespread recognition.
Biotech firms are often active in the medical and pharmaceutical sectors. As a result, they must undergo rigorous trials and screening before receiving distribution clearance. This makes them a dangerous early investment, as their completion might take years. Frequently, unanticipated obstacles and complexities develop, prolonging the needed time and delaying the potential ROI.
As with other penny stocks, it is prudent to diversify your portfolio and invest only what you are willing to lose. Consequently, you may reduce risk and put your assets on the back burner.
Real-time News
